Imaging Protocols

• US 20090304582A1
• Filed: 07/19/2006
• Published: 12/10/2009
• Est. Priority Date: 07/19/2005
• Status: Active Grant

• Current Assignee: Spectrum Dynamics Medical Ltd
• Original Assignee: Spectrum Dynamics LLC
• Inventors: Dickman, Dalia, Ben-Haim, Simona, Rousso, Benny, Ben-Haim, Shlomo, Vallabhajosula, Shankar, Nagler, Michael, Bronshtine, Zohar, Nir, Yael
• Granted Patent: US 8,644,910 B2
• Time in Patent Office: Days
• US Class Current: 424/1.610
• CPC Class Codes: A61B 5/02755 Radioactive tracers
• CPC Class Codes: A61B 5/06 Devices, other than using radiation, for detecting or locating foreign bodies for removing same A61B17/50 ; determining position of probes within or on the body of the patient
• CPC Class Codes: A61B 5/4064 Evaluating the brain A61B5/031, A61B5/369, A61B5/14553 take precedence
• CPC Class Codes: A61B 5/4076 Diagnosing or monitoring particular conditions of the nervous system A61B5/4821, A61B5/4824 take precedence
• CPC Class Codes: A61B 5/4088 Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
• CPC Class Codes: A61B 5/411 Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance
• CPC Class Codes: A61B 5/415 the glands, e.g. tonsils, adenoids or thymus
• CPC Class Codes: A61B 5/417 the bone marrow
• CPC Class Codes: A61B 5/418 lymph vessels, ducts or nodes
• CPC Class Codes: A61B 5/4519 Muscles A61B5/389, A61B5/224 take precedence
• CPC Class Codes: A61B 6/037 Emission tomography
• CPC Class Codes: A61B 6/4057 by using radiation sources located in the interior of the body A61B6/037 takes precedence
• CPC Class Codes: A61B 6/4258 for detecting non x-ray radiation, e.g. gamma radiation A61B6/037 takes precedence
• CPC Class Codes: A61B 6/4291 the detector being combined with a grid or grating
• CPC Class Codes: A61B 6/4488 Means for cooling A61B6/045 takes precedence
• CPC Class Codes: A61B 6/501 for diagnosis of the head, e.g. neuroimaging or craniography
• CPC Class Codes: A61B 6/502 for diagnosis of breast, i.e. mammography
• CPC Class Codes: A61B 6/503 for diagnosis of the heart
• CPC Class Codes: A61B 6/504 for diagnosis of blood vessels, e.g. by angiography
• CPC Class Codes: A61B 6/507 for determination of haemodynamic parameters, e.g. perfusion CT
• CPC Class Codes: A61B 6/5247 : combining images from an ionising-radiation diagnostic technique and a non-ionising radiation diagnostic technique, e.g. X-ray and ultrasound
• CPC Class Codes: A61B 6/583 : using calibration phantoms
• CPC Class Codes: A61B 8/0891 : for diagnosis of blood vessels
• CPC Class Codes: A61B 8/4416 : related to combined acquisition of different diagnostic modalities, e.g. combination of ultrasound and X-ray acquisitions
• CPC Class Codes: A61K 51/02 : characterised by the carrier , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
• CPC Class Codes: A61K 51/04 : Organic compounds
• CPC Class Codes: A61K 51/0402 : carboxylic acid carriers, fatty acids amino acids A61K51/0406
• CPC Class Codes: A61K 51/0476 : complexes from monodendate ligands, e.g. sestamibi
• CPC Class Codes: A61K 51/0478 : complexes from non-cyclic ligands, e.g. EDTA, MAG3
• CPC Class Codes: A61K 51/048 : DTPA (diethylenetriamine tetraacetic acid)
• CPC Class Codes: A61K 51/0489 : Phosphates or phosphonates, e.g. bone-seeking phosphonates; phospholipids: A61K51/0408; nucleotides or nucleic acids: A61K51/0491
• CPC Class Codes: A61K 51/0491 : Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
• CPC Class Codes: A61K 51/1203 : in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors

Abstract

Protocols for radioimaging an event or disorder are provided. An exemplary protocol comprises a method of radioimaging a myocardial perfusion, the method comprising in sequence:

• • (a) administering to a subject about 3 mCi Tl201 thallous chloride;
  • (b) allowing said subject to rest;
  • (c) radioimaging a heart of said subject;
  • (d) subjecting said subject to a physical stress;
  • (e) administering to said subject at a peak of said physical stress about 20-30 mCi Tc99m sestamibi; and
  • (f) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.

Claims

1. A method of radioimaging a myocardial perfusion, the method comprising in sequence:

(a) administering to a subject about 3 mCi Tl201 thallous chloride;

(b) allowing said subject to rest;

(c) radioimaging a heart of said subject;

(d) subjecting said subject to a physical stress;

(e) administering to said subject at a peak of said physical stress about 20-30 mCi Tc99m sestamibi; and

(f) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.

2. The method of claim 1, comprising at least one or more of the following:

(1) step (b) is for about 10-15 minutes;

(2) step (c) is for about 2 minutes;

(3) step (d) is effected about 2 minutes following step (c);

(4) step (f) is effected about 30-60 minutes following step (d); and

(5) step (f) is for about 2 minutes.

3. The method of claim 1, effected as described in Table 1.

6. The method of claim 1, effected as described in Table 2.

4. A method of radioimaging a myocardial perfusion, the method comprising in sequence:

(a) administering to a subject about 8-10 mCi Tc99m sestamibi;

(b) allowing said subject to rest;

(c) radioimaging a heart of said subject;

(d) subjecting said subject to a physical stress;

(e) administering to said subject at a peak of said physical stress about 20-30 mCi Tc99m sestamibi; and

(f) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.

5. The method of claim 4, comprising at least one or more of the following:

(1) step (b) is for about 30 minutes;

(2) step (c) is for about 2 minutes;

(3) step (d) is effected immediately following step (c);

(4) step (f) is effected about 30-60 minutes following step (e); and

(5) step (f) is for about 2 minutes.

7. A method of radioimaging a myocardial perfusion, the method comprising in sequence:

(a) administering to a subject about 3 mCi Tl201 thallous chloride;

(b) allowing said subject to rest;

(c) radioimaging a heart of said subject;

(d) subjecting said subject to a pharmacological stress;

(e) administering to said subject at a peak of said pharmacological stress about 20-30 mCi Tc99m sestamibi; and

(f) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.

8. The method of claim 7, comprising at least one or more of the following:

(1) step (b) is for about 2 minutes;

(2) step (c) is for about 2 minutes;

(3) step (d) is effected immediately following step (c);

(4) step (e) is effected about 2 minutes following step (d);

(5) step (f) is effected immediately following step (e);

(6) step (f) is for about 2 minutes; and

(7) said pharmacological stress is adenosine or dipyridamole;

9. The method of claim 7, effected as described in Table 3.

10. A method of radioimaging a myocardial perfusion, the method comprising in sequence:

(a) administering to a subject about 8-10 mCi Tc99m sestamibi;

(b) radioimaging a heart of said subject;

(c) subjecting said subject to a pharmacological stress;

(d) administering to said subject at a peak of said pharmacological stress about 20-30 mCi Tc99m sestamibi; and

(e) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.

11. The method of claim 10, comprising at least one or more of the following:

(1) step (b) is immediately following step (a);

(2) step (b) is for about 2 minutes;

(3) step (c) is effected immediately following step (b);

(4) step (d) is effected about 2 minutes following step (c);

(5) step (e) is effected immediately following step (d);

(6) step (e) is for about 2 minutes; and

(7) said pharmacological stress is adenosine or dipyridamole.

12. The method of claim 10, effected as described in Table 4.

13. A method of radioimaging a myocardial perfusion, the method comprising in sequence:

(a) administering to a subject about 3 mCi Tl201 thallous chloride;

(b) allowing said subject to rest;

(c) radioimaging a heart of said subject;

(d) subjecting said subject to a physical stress;

(e) administering to said subject at a peak of said physical stress about 20-30 mCi Tc99m sestamibi; and

(f) radioimaging said heart of said subject immediately following said peak stress, thereby radioimaging a myocardial perfusion.

14. The method of claim 13, comprising at least one or more of the following:

(1) step (b) is for about 15 minutes;

(2) step (c) is for about 2 minutes;

(3) step (e) is effected about 30-60 minutes following step (d); and

(4) step (f) is for about 2 minutes.

15. The method of claim 13, effected as described in Table 5.

16. A method of radioimaging a myocardial perfusion, the method comprising in sequence:

(a) administering to a subject about 20-30 mCi Tc99m sestamibi;

(b) allowing said subject to rest;

(c) radioimaging a heart of said subject;

(d) subjecting said subject to a physical stress;

(e) administering to said subject at a peak of said physical stress about 3 mCi Tl201 thallous chloride;

(f) radioimaging said heart of said subject; and

(g) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.

17. The method of claim 16, comprising at least one or more of the following:

(1) step (b) is for about 15-30 minutes;

(2) step (c) is for about 2 minutes;

(3) step (d) is effected immediately following step (c);

(4) step (f) is effected about 10-15 minutes following step (e);

(5) step (f) is for about 4 minutes;

(6) step (g) is effected about 4 hours following step (f); and

(7) step (g) is for about 6 minutes.

18. The method of claim 16, effected as described in Table 6.

19. A method of radioimaging a myocardial perfusion, the method comprising in sequence:

(a) administering to a subject about 3 mCi Tc99m sestamibi;

(b) allowing said subject to rest;

(c) radioimaging a heart of said subject;

(d) subjecting said subject to a pharmacological stress;

(e) administering to said subject at a peak of said pharmacological stress about 3 mCi Tl201 thallous chloride;

(f) radioimaging said heart of said subject; and

(g) radioimaging said heart of said subject, thereby radioimaging a myocardial perfusion.

20. The method of claim 19, comprising at least one or more of the following:

(1) step (b) is for about 15-30 minutes;

(2) step (c) is for about 2 minutes;

(3) step (d) is effected immediately following step (c);

(4) step (e) is effected about 2 minutes following step (d);

(5) step (f) is effected immediately following step (e);

(6) step (f) is for about 4 minutes;

(7) step (g) is effected about 4 hours following step (f);

(8) step (g) is for about 6 minutes; and

(9) said pharmacological stress is adenosine or dipyridamole.

21-540. -540. (canceled)